H.C. Wainwright Forecasts 2026 Data Readouts for Climb Bio’s (CLYM) Budoprutug Across Clinical Tracks

Climb Bio Inc. (NASDAQ:CLYM) is one of the best biotech penny stocks to buy according to analysts. On December 18, H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Climb Bio to $11 from $9, while maintaining a Buy rating on the shares. This sentiment was announced as the firm believes that Budoprutug’s progress across clinical tracks will culminate in the release of data readouts during 2026.

The company is currently focused on two primary assets: Budoprutug, which is an anti-CD19 antibody targeting B-cell mediated diseases, and CLYM116, which is an anti-APRIL antibody for IgA nephropathy. Leadership characterized 2026 as a data-rich year, with multiple readouts expected to guide the next phase of development for both programs.

H.C. Wainwright Forecasts 2026 Data Readouts for Climb Bio’s (CLYM) Budoprutug Across Clinical Tracks

Climb Bio Inc. (NASDAQ:CLYM) initiated the PrisMN Phase 2 trial for Budoprutug in Primary Membranous Nephropathy/pMN in Q3 2025. This open-label, dose-ranging study aims to evaluate safety, pharmacokinetics, and preliminary efficacy, specifically complete and partial remission, to identify a dose for Phase 3. Additionally, a Phase 1 trial for a subcutaneous formulation achieved its first patient in, with enrollment currently ongoing to assess bioavailability and pharmacodynamics. Initial data from this SC formulation trial is expected in the first half of 2026.

The company is also conducting two other major trials for Budoprutug. An open-label Phase 1b/2a trial is enrolling patients with Immune Thrombocytopenia to monitor platelet counts and B-cell depletion. Simultaneously, a Phase 1b trial is evaluating the drug’s activity in Systemic Lupus Erythematosus patients following a single intravenous dose. The company anticipates releasing initial data, including preliminary efficacy results, for both the ITP and SLE programs in H2 2026.

Climb Bio Inc. (NASDAQ:CLYM) is a clinical-stage biotechnology company that develops therapies for immune-mediated diseases.

While we acknowledge the potential of CLYM to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CLYM and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.